Brain, Vol. 125, No. 11, 2381-2391,
November 2002
© 2002 Oxford University Press
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
1 Department of Neuroimmunology, Max Planck Institute of Neurobiology, Martinsried, 2 Institute for Clinical Neuroimmunology and Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany and 3 Department of Neurology, Karl-Franzens-University Graz, Austria
Correspondence to: Dr R. Hohlfeld, Institute for Clinical Neuroimmunology, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, D-81366 Munich, Germany E-mail: hohlfeld{at}neuro.mpg.de
The clinical effects of glatiramer acetate (GA), an approved therapy for multiple sclerosis, are thought to be largely mediated by a T-helper 1 (TH1) to T-helper 2 (TH2) shift of GA-reactive T-lymphocytes. Current theories propose that activated GA-reactive TH2 cells penetrate the CNS, release anti-inflammatory cytokines such as interleukin (IL)-4, IL-5 and IL-10, and thus inhibit neighbouring inflammatory cells by a mechanism termed ‘bystander suppression’. We demonstrate that both GA-specific TH2 and TH1 cells produce the neurotrophin brain-derived neurotrophic factor (BDNF). As the signal-transducing receptor for BDNF, the full-length 145 tyrosine kinase receptor (trk) B, is expressed in multiple sclerosis lesions, it is likely that the BDNF secreted by GA-reactive TH2 and TH1 has neurotrophic effects in the multiple sclerosis target tissue. This may be an additional mechanism of action of GA, and may be relevant for therapies with altered peptide ligands in general. To demonstrate that GA-reactive T cells produce BDNF, we selected four GA-specific, long-term T-cell lines (TCLs), which were characterized according to their cytokine profile by intracellular double-fluorescence flow cytometry. Three TCLs (isolated from a normal subject) had the phenotypes TH1, TH1/TH0, and TH0; the fourth, derived from a GA-treated patient, had the phenotype TH2. To demonstrate BDNF production, we used a combination of RT-PCR (reverse transcription-polymerase chain reaction) and two specially designed techniques for BDNF protein detection: one was based on ELISA (enzyme-linked immunosorbent assay) of supernatants from co-cultures of GA-specific TCLs plus GA-pulsed antigen-presenting cells, and the other on the direct intracellular staining of BDNF in individual T cells and flow cytometric analysis. The different assays and different TCLs yielded similar, consistent results. All four GA-specific T-cell lines, representing the major different TH phenotypes, could be stimulated to produce BDNF.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Roy, X. Liu, and K. Pahan Myelin Basic Protein-primed T Cells Induce Neurotrophins in Glial Cells via {alpha}5beta3 Integrin J. Biol. Chem., November 2, 2007; 282(44): 32222 - 32232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. W. Yong, F. Giuliani, M. Xue, A. Bar-Or, and L. M. Metz Experimental models of neuroprotection relevant to multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S32 - S37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld, M. Kerschensteiner, and E. Meinl Dual role of inflammation in CNS disease Neurology, May 29, 2007; 68(22_suppl_3): S58 - S63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sarchielli, M. Zaffaroni, A. Floridi, L. Greco, A. Candeliere, A. Mattioni, S. Tenaglia, M. Di Filippo, and P. Calabresi Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-{beta} 1a, and high doses of immunoglobulins Multiple Sclerosis, April 1, 2007; 13(3): 313 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Butovsky, M. Koronyo-Hamaoui, G. Kunis, E. Ophir, G. Landa, H. Cohen, and M. Schwartz From the Cover: Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1 PNAS, August 1, 2006; 103(31): 11784 - 11789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Gordon, C. Doorish, J. Montes, R. L. Mosley, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, et al. Randomized controlled phase II trial of glatiramer acetate in ALS Neurology, April 11, 2006; 66(7): 1117 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Aharoni, R. Eilam, H. Domev, G. Labunskay, M. Sela, and R. Arnon The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice PNAS, December 27, 2005; 102(52): 19045 - 19050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Allie, L. Hu, K. M. Mullen, S. Dhib-Jalbut, and P. A. Calabresi Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy Arch Neurol, June 1, 2005; 62(6): 889 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hong, N. Li, X. Zhang, B. Zheng, and J. Z. Zhang Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3 PNAS, May 3, 2005; 102(18): 6449 - 6454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Patke and D. L. Farber Modulation of Memory CD4 T Cell Function and Survival Potential by Altering the Strength of the Recall Stimulus J. Immunol., May 1, 2005; 174(9): 5433 - 5443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld and H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines PNAS, October 5, 2004; 101(suppl_2): 14599 - 14606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Weber, M. Starck, S. Wagenpfeil, E. Meinl, R. Hohlfeld, and C. Farina Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo Brain, June 1, 2004; 127(6): 1370 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld Immunologic factors in primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S16 - S22. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, June 1, 2004; 10(1_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
J. Kipnis, H. Cohen, M. Cardon, Y. Ziv, and M. Schwartz T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions PNAS, May 25, 2004; 101(21): 8180 - 8185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hohlfeld Immunologic factors in primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S16 - S22. [Abstract] [PDF]
|
|
|
|
|
|
R. R. Kreitman and F. Blanchette On the horizon: possible neuroprotective role for glatiramer acetate Multiple Sclerosis, May 1, 2004; 10(3_suppl): S81 - S89. [Abstract] [PDF]
|
|
|
|
|
|
D Teitelbaum, T Brenner, O Abramsky, R Aharoni, M Sela, and R Arnon Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy Multiple Sclerosis, December 1, 2003; 9(6): 592 - 599. [Abstract] [PDF]
|
|
|
|
|
|
R. Aharoni, B. Kayhan, R. Eilam, M. Sela, and R. Arnon Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ PNAS, November 25, 2003; 100(24): 14157 - 14162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Bradl and R Hohlfeld Molecular pathogenesis of neuroinflammation J. Neurol. Neurosurg. Psychiatry, October 1, 2003; 74(10): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bergamaschi Glatiramer acetate treatment in Devic's neuromyelitis optica Brain, June 1, 2003; 126(6): E1 - E1. [Full Text] [PDF]
|
|
|
|
|
|
R. Gold and C. Linington Reply Brain, June 1, 2003; 126(6): E1 - E1. [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos and P. Duda The Janus face of CNS-directed autoimmune response: a therapeutic challenge Brain, November 1, 2002; 125(11): 2379 - 2380. [Full Text] [PDF]
|
|